/EXAS
EXAS Stock - Exact Sciences Corporation
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$101.82+0.43%
+$0.44 (+0.43%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).27
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.63
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-11.5%upside
Target: $90.11
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EXAS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$100.80 – $102.84
TARGET (TP)$90.06
STOP LOSS$93.67
RISK/REWARD1:-1.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.42
52W High$102.66
52W Low$38.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.76B | $2.50B | $2.08B | $1.77B | $1.49B |
| Gross Profit | $1.92B | $1.76B | $1.42B | $1.31B | $1.14B |
| Gross Margin | 69.5% | 70.5% | 68.3% | 74.0% | 76.2% |
| Operating Income | $-1,048,703,000 | $-215,012,000 | $-593,511,000 | $-855,678,000 | $-767,696,000 |
| Net Income | $-1,028,857,000 | $-204,149,000 | $-623,506,000 | $-595,625,000 | $-823,605,000 |
| Net Margin | -37.3% | -8.2% | -29.9% | -33.7% | -55.2% |
| EPS | $-5.59 | $-1.13 | $-3.54 | $-3.48 | $-5.45 |
Company Overview
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
67%
Hold / Neutral
5
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
10 Bullish5 Neutral/Bearish
Price Targets
$73
Average Target
↓ 28.6% Downside
Now
$35
Low
$73
Average
$95
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 10th 2025 | Mizuho | Initiation | Outperform | $60 |
| March 13th 2025 | RBC Capital Mkts | Initiation | Sector Perform | $52 |
| January 23rd 2025 | Barclays | Initiation | Overweight | $70 |
| August 28th 2024 | Wells Fargo | Initiation | Overweight | $75 |
| June 27th 2024 | Scotiabank | Initiation | Sector Outperform | $70 |
| June 3rd 2024 | Jefferies | Resumed | Buy | $75 |
| January 2nd 2024 | The Benchmark Company | Upgrade | Buy | $91 |
| December 14th 2023 | Guggenheim | Initiation | Buy | $90 |
| December 13th 2023 | Wolfe Research | Initiation | Outperform | $95 |
| October 10th 2023 | Piper Sandler | Upgrade | Overweight | $90 |
| September 28th 2023 | Bernstein | Initiation | Outperform | $83 |
| August 2nd 2023 | The Benchmark Company | Downgrade | Hold | - |
| May 10th 2023 | Craig Hallum | Upgrade | Buy | $85← $55 |
| May 5th 2023 | UBS | Initiation | Neutral | $73 |
| March 9th 2023 | Citigroup | Upgrade | Buy | $90← $70 |
Earnings History & Surprises
EXASBeat Rate
72%
Last 18 quarters
Avg Surprise
+114.2%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$0.24
Q4 2025
EPS Surprise History
Q1 24
+49.1%
$-0.27vs$-0.53
Q2 24
-5.3%
$-0.50vs$-0.47
Q3 24
+75.7%
$-0.09vs$-0.37
Q4 24
-7.2%
$-0.21vs$-0.20
Q1 25
+79.3%
$-0.06vs$-0.29
Q2 25
+43.2%
$-0.21vs$-0.37
Q3 25
+1200.0%
$0.22vs$-0.02
Q4 25
+492.0%
$0.24vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | — | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.06 | $0.24 | +492.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.02 | $0.22 | +1200.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.37 | $-0.21 | +43.2% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $-0.29 | $-0.06 | +79.3% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.20 | $-0.21 | -7.2% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $-0.37 | $-0.09 | +75.7% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.47 | $-0.50 | -5.3% | ✗ MISS |
Q1 2024 | Feb 21, 2024 | $-0.53 | $-0.27 | +49.1% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-0.48 | $0.00 | +100.9% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.50 | $-0.45 | +10.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.79 | $-0.42 | +46.8% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $-0.90 | $-0.72 | +20.0% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.10 | $-0.84 | +23.6% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-1.07 | $-0.94 | +12.1% | ✓ BEAT |
Q2 2022 | Apr 26, 2022 | $-1.12 | $-1.04 | +7.1% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-0.91 | $-1.28 | -40.7% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-0.89 | $-0.97 | -9.0% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $-0.72 | $-1.03 | -43.1% | ✗ MISS |
Latest News
Exact Sciences Enrolls First Patient In CRANE Trial In Japan To Evaluate Multi-Cancer Early Detection Test
📈 PositiveBenzinga•Dec 18, 2025, 09:23 PM
Canaccord Genuity Downgrades Exact Sciences to Hold, Raises Price Target to $105
➖ NeutralBenzinga•Nov 25, 2025, 01:19 PM•Also:
Benchmark Downgrades Exact Sciences to Hold
📉 NegativeBenzinga•Nov 24, 2025, 01:58 PM
Jefferies Downgrades Exact Sciences to Hold, Raises Price Target to $105
➖ NeutralBenzinga•Nov 24, 2025, 12:25 PM•Also:
Wells Fargo Downgrades Exact Sciences to Equal-Weight, Raises Price Target to $105
➖ NeutralBenzinga•Nov 21, 2025, 03:30 PM
William Blair Downgrades Exact Sciences to Market Perform
📉 NegativeBenzinga•Nov 21, 2025, 03:12 PM
Guggenheim Downgrades Exact Sciences to Neutral
➖ NeutralBenzinga•Nov 21, 2025, 02:08 PM
Barclays Downgrades Exact Sciences to Equal-Weight, Raises Price Target to $105
➖ NeutralBenzinga•Nov 21, 2025, 01:39 PM•Also:
EQIX stock has given up its prior gain. Exact Sciences shares were trading higher after Abbott agreed to acquire the company for $105 per share in a deal valued at about $20 billion.
➖ NeutralBenzinga•Nov 20, 2025, 05:23 PM•Also: ,
Exact Sciences rises as Abbott moves to buy cancer test maker for $21B
📈 PositiveSeeking Alpha•Nov 20, 2025, 12:53 PM•Also:
Exact Sciences shares are trading higher after Abbott agreed to acquire the company for $105 per share in a deal valued at about $20 billion.
📈 PositiveBenzinga•Nov 20, 2025, 12:44 PM•Also:
CORRECTION: Exact Sciences Ticker Is 'EXAS'
➖ NeutralBenzinga•Nov 20, 2025, 12:44 PM
Abbott Signs Agreement To Acquire Exact Sciences For $105/Share At ~$20B Equity Value
📈 PositiveBenzinga•Nov 20, 2025, 12:31 PM•Also:
Exact Sciences likely needs to see over $100/share in takeover - analyst
➖ NeutralSeeking Alpha•Nov 19, 2025, 08:20 PM
Abbott Laboratories shares are trading lower after Bloomberg reported the company is weighing a takeover of Exact Sciences.
📉 NegativeBenzinga•Nov 19, 2025, 07:08 PM•Also:
Exact Sciences shares are trading higher after Bloomberg reported that Abbott is weighing a takeover of the company.
📈 PositiveBenzinga•Nov 19, 2025, 07:08 PM•Also:
Exact Sciences jumps on report Abbott nears takeover
📈 PositiveSeeking Alpha•Nov 19, 2025, 06:55 PM•Also:
Exact Sciences Shares Resume Trade
➖ NeutralBenzinga•Nov 19, 2025, 06:48 PM
UPDATE: 'Abbott Weighs Takeover of Cancer Test Maker Exact Sciences' - Bloomberg News
📈 PositiveBenzinga•Nov 19, 2025, 06:41 PM•Also:
Exact Sciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 13.95%
📈 PositiveBenzinga•Nov 19, 2025, 06:39 PM
Frequently Asked Questions about EXAS
What is EXAS's current stock price?
Exact Sciences Corporation (EXAS) is currently trading at $101.82 per share. The stock has moved +0.43% today.
What is the analyst price target for EXAS?
The average analyst price target for EXAS is $90.06, based on 1 analyst.
What sector is Exact Sciences Corporation in?
Exact Sciences Corporation operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is EXAS's market cap?
Exact Sciences Corporation has a market capitalization of $19.29 billion, making it a large-cap company.
Does EXAS pay dividends?
No, Exact Sciences Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBIO
BridgeBio Pharma, Inc.
$76.30
Mkt Cap: $14.5B
DOCS
Doximity, Inc.
$43.65
Mkt Cap: $8.2B
GH
Guardant Health, Inc.
$99.74
Mkt Cap: $12.4B
ICLR
ICON Public Limited Company
$173.77
Mkt Cap: $13.3B
QGEN
Qiagen N.V.
$45.58
Mkt Cap: $9.9B
ROIV
Roivant Sciences Ltd.
$22.41
Mkt Cap: $15.6B
RVMD
Revolution Medicines, Inc.
$78.78
Mkt Cap: $15.2B
RVTY
Revvity, Inc.
$96.24
Mkt Cap: $11.4B
SMMT
Summit Therapeutics Inc.
$17.82
Mkt Cap: $13.3B
VTRS
Viatris Inc.
$11.93
Mkt Cap: $13.7B
Explore stocks similar to EXAS for comparison